Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures

Hopital Foch

Status and phase: Completed; Phase 2

Conditions: Radiotherapy Side Effect; Cervical Spasm; Botulinum Toxin

Treatments: Drug: Botulinum toxin A; Procedure: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02986880

2011-000889-35 (EudraCT Number)

2011/08

Details and patient eligibility

About

The main objective of the study is to estimate the efficiency and to determine the optimal dose of Botulinum toxin A, administered by intramuscular way in cervical spasms after radiotherapy, as well as the optimal sites for these injections.

The concerned muscular groups are the sternocleidomastoid (SCM), the trapezius muscle and the splenius capitis.

Enrollment: 14 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients from 18 to 75 years old;
• malignant Tumor of aerodigestive ways, in forgiveness;
• Treatment containing the external radiotherapy ended since > 6 months
• Life expectancy > 6 months;
• patient complaining from cervical spasms with functional disability;
• Negative Pregnancy test;
• Women under effective contraception;
• Patients benefiting from a national insurance scheme;
• Patient having given a written consent.

Exclusion criteria

• Cervico-facial Surgery with reconstruction by pedicled flap
• Implantable Chamber with catheter in the internal jugular vein near the spasm;
• Muscular, neurological Pathology or malformative pulling a disorder of perception of the pain, an amyotrophy, a muscular weakness affecting the cervical axis or the upper limbs;
• Disorder generalized by the muscular activity (ex myasthenia);
• Cervical osseous or muscular Pathology pulling pains and disability before the beginning of the treatment (cervical degenerative osteoarthritis diagnosed to the cervical radiography, the slipped disc);
• Previous cervical injection of botulinum toxin ;
• Local Infection at the level of one of the sites proposed for injection;
• Histories of epilepsy;
• Patients presenting a hypersensitivity to the botulinum neurotoxin A or in one of its excipients;
• Patients under anticoagulation therapy, Under antibiotic treatment by aminoglycosides or amino 4 quinoline, under myorelaxant treatment or that must undergo an intervention with curarisation;
• Patients for whom a surgical operation is planned in the zone interested in the treatment
• Pregnant or breast-feeding Women;
• Patients for whom questionnaires will not be assessable (handicaps of communication, patient not speaking French, etc.).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

14 participants in 10 patient groups, including a placebo group

Group D1

Experimental group

Description:

Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.

Treatment:

Drug: Botulinum toxin A

Group D2

Experimental group

Description:

Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.

Treatment:

Drug: Botulinum toxin A

Group D3

Experimental group

Description:

Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.

Treatment:

Drug: Botulinum toxin A

Group A1

Experimental group

Description:

Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.

Treatment:

Drug: Botulinum toxin A

Group A2

Experimental group

Description:

Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.

Treatment:

Drug: Botulinum toxin A

Group A3

Experimental group

Description:

Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.

Treatment:

Drug: Botulinum toxin A

Group F1

Experimental group

Description:

Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.

Treatment:

Drug: Botulinum toxin A

Group F2

Experimental group

Description:

Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.

Treatment:

Drug: Botulinum toxin A

Group F3

Experimental group

Description:

Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.

Treatment:

Drug: Botulinum toxin A

Group P

Placebo Comparator group

Description:

Patients receiving placebo in the third muscles groups

Treatment:

Procedure: Placebo